State Street My2029公司債券主動型ETF MYCI 深 滬
等待開盤 06-24 09:30:00 美东时间
24.72
+0.035
+0.14%
華盛通- 最 高24.73
- 今 開24.72
- 成交量 7546股
- 最 低 24.7199
- 昨 收 24.685
- 總市值 3460.80万
- 52周最高 24.8517
- 市盈率 靜 --
- 換手率 0.54%
- 52周最低 23.6968
- 委 比 0.00%
- 總股本 140.00万
- 歷史最高 24.8517
- 量 比 1.44
- 振 幅 0.04%
- 歷史最低 22.5552
- 每 手 1
- 風險率 0.31%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BRIEF-Palvella Therapeutics Reports Full Year 2025 Financial Results And Provides Corporate Update
BRIEF-Palvella Therapeutics Reports Full Year 2025 Financial Results And Provides Corporate Update March 31 (Reuters) - Palvella Therapeutics Inc PVLA.O : PALVELLA THERAPEUTICS REPORTS FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE PALVELLA THERAPEUTICS - NDA FOR QTORIN RAPAMYCIN FOR
03-31 19:41
BRIEF-Microport Neuroscientific Says FDA Grants Breakthrough Device Designation To Apollo Dream Rapamycin Stent System
BRIEF-Microport Neuroscientific Says FDA Grants Breakthrough Device Designation To Apollo Dream Rapamycin Stent System March 18 (Reuters) - MicroPort NeuroScientific Corp 2172.HK : FDA GRANTS BREAKTHROUGH DEVICE DESIGNATION TO APOLLO DREAM RAPAMYCIN STENT SYSTEM Further company coverage: 2172.HK ((
03-18 18:30
Moleculin Biotech Secures Japan Patent Allowance For Liposomal Annamycin Method
Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today announced that the Japan Patent Office (JPO) has issued a notice of allowance for Patent Application No. 2021-577862 titled, "METHOD OF
02-17 21:37
Moleculin Biotech Receives Notice of Allowance for Japanese Patent Covering Liposomal Annamycin
Moleculin Biotech Receives Notice of Allowance for Japanese Patent Covering Liposomal Annamycin Moleculin Biotech Inc. announced that the Japan Patent Office has issued a notice of allowance for its patent application titled "METHOD OF RECONSTITUTING LIPOSOMAL ANNAMYCIN." A patent from the applicati
02-17 21:35
BRIEF-Palvella Therapeutics Announces Positive Topline Results From Phase 2 TOIVA Clinical Trial Of Qtorin™
Dec 15 (Reuters) - Palvella Therapeutics Inc PVLA.O: PALVELLA THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2 TOIVA CLINICAL TRIAL OF QTORIN™ 3.9% RAPAMYCIN ANHYDROUS GEL (QTORIN™ RAPAMYC...
2025-12-15 19:19
BRIEF-Moleculin Announces New Annamycin Collaboration In Brain Tumors
Dec 8 (Reuters) - Moleculin Biotech Inc MBRX.O: MOLECULIN ANNOUNCES NEW ANNAMYCIN COLLABORATION IN BRAIN TUMORS MOLECULIN BIOTECH INC - ENTERS RESEARCH AGREEMENT WITH CIC BIOMAGUNE Source text: ID:nGN...
2025-12-08 21:21
BRIEF-Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer
Oct 23 (Reuters) - Moleculin Biotech Inc MBRX.O: MOLECULIN ANNOUNCES NEW INVESTIGATOR-INITIATED STUDY OF ANNAMYCIN FOR TREATING PANCREATIC CANCER MOLECULIN BIOTECH INC - ESTIMATES TRIAL COST AT $1 MIL...
2025-10-23 20:44
BRIEF-U.S. FDA awards Year Two funds to Palvella's Phase 3 Selva trial
Oct 13 (Reuters) - Palvella Therapeutics Inc PVLA.O: U.S. FOOD AND DRUG ADMINISTRATION AWARDS YEAR TWO PROCEEDS FROM ORPHAN PRODUCTS GRANT SUPPORTING PALVELLA THERAPEUTICS’ PHASE 3 SELVA TRIAL OF QTOR...
2025-10-13 19:40
BRIEF-Palvella Therapeutics Announces Expansion of QTORIN Rapamycin’s Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved Therapies
Sept 24 (Reuters) - Palvella Therapeutics Inc PVLA.O: PALVELLA THERAPEUTICS ANNOUNCES EXPANSION OF QTORIN™ RAPAMYCIN’S DEVELOPMENT INTO CLINICALLY SIGNIFICANT ANGIOKERATOMAS, A RARE, CHRONICALLY DEBIL...
2025-09-24 18:04
BRIEF-Palvella Completes Phase 2 TOIVA Trial Enrollment for QTORIN Rapamycin in Treating Cutaneous Venous Malformations
Sept 15 (Reuters) - Palvella Therapeutics Inc PVLA.O: PALVELLA THERAPEUTICS COMPLETES ENROLLMENT IN PHASE 2 TOIVA TRIAL OF QTORIN™ RAPAMYCIN FOR CUTANEOUS VENOUS MALFORMATIONS PALVELLA THERAPEUTICS IN...
2025-09-15 19:34
